Lytix Biopharma is a clinical stage pharmaceutical company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. 

Lytix’ product candidate LTX-315 is a first-in-class* oncolytic peptide with the potential to fully personalize immunotherapy. LTX-315 is developed for intratumoral treatment of solid tumors turning cold tumors hot. The phase I/II trial has demonstrated an acceptable and predictable safety profile with promising efficacy signals in monotherapy and combination therapy and the development is proceeding into phase II trials.

LTX-315 turns cold tumors hot by reshaping the tumor microenvironment through an effective release of potent immune stimulating molecules and tumor antigens. Reshaping the tumor microenvironment by LTX-315 triggers the immune system to recognize, infiltrate and attack the cancer cells, opening up the tumor for a variety of combination treatments including the marketed checkpoint inhibitors.

Currently, LTX-315 is developed for second line treatment of metastatic malignant melanoma and metastatic triple negative breast cancer (“TNBC”) in combination with checkpoint inhibitors, soft-tissue sarcoma as a pre-treatment with adoptive T cell therapy and as a neo-adjuvant (prior to curative surgery) therapy in head and neck cancer.

The Company believes LTX-315 is one of the most promising drug candidates with the potential to fully personalize immunotherapy by its mode of action to use the patient’s own tumor as its own vaccine, expose the immune system to one patient’s own cancer antigens, and to generate patient specific antitumor immunity. LTX-315 will convert cancers that are not recognized by the immune system and that are immunologically cold and unresponsive to immune therapy (the majority of cancers) to immunologically hot and, as a result, responsive to combination therapies with checkpoint inhibitors. LTX-315 has the potential to be used across several cancer indications, in various stages of cancer (early versus advanced), in combination with, or after, current standard of care therapy, primarily in combination with other immune therapies like checkpoint inhibitors or with chemotherapies.

* ’’First-in-class’’ refers to a pharmaceutical which often has a new mechanism of action which differs from existing therapies, FDA Novel Drugs Summary, 2016.


For more information, please email us at:

Top 20 shareholders of Lytix Biopharma AS - as of 15 May 2018
Shareholder Number of shares % of shares
TAJ Holding AS 3 268 291 17.0
North Murray AS* 2 222 463 11.5
3 T PRODUKTER 1 525 431 7.9
CARE Holding AS* 1 483 080 7.7
Picasso Kapital AS 1 097 860 5.7
Rothesay Limited 610 184 3.2
Brødrene Karlsen Holding AS 609 273 3.2
Mikael Lönn 570 717 3.0
Lysnes Invest AS* 555 973 2.9
Norinnova Invest AS 542 510 2.8
Hopen Invest AS* 432 363 2.2
LMK Venture AB 420 363 2.2
Kreftforeningen 218 000 1.1
Per Strand Eiendom AS 196 350 1.0
4LB INVEST AS 160 040 0.8
Norinnova Technology Transfer AS 155 790 0.8
John Sigurd Svendsen 152 420 0.8
Sparebank1 Nord-Norge Portefølje AS 151 820 0.8
Jahatt AS 143 640 0.7
AGIR AS 141 334 0.7
Other shareholders 4 591 018 23.9
Total 19 248 920

*Members of the board and/or management of Lytix Biopharma ASA are represented.


* List of insiders within the Board and Management
Lytix Biopharma Board Lytix Biopharma Management
Espen Johnsen, Chairman Edwin Klumper, CEO
Gert W. Munthe Torbjørn Furuseth
Debasish Roychowdhury Hamina Patel
Bernt Endrerud Øystein Rekdal